Evidence map›Paper›PMID 31803736›Full record

ReviewFrontiers in bioengineering and biotechnology2019

The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment.

Andrei Belousov, Sergei Titov, Nikita Shved, Mikhail Garbuz, Grigorii Malykin, Valeriia Gulaia, Alexander Kagansky, Vadim Kumeiko

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 89 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. A Synopsis of Biomarkers in Glioblastoma: Past and Present.Current issues in molecular biology · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Andrei BelousovSchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Sergei TitovSchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Nikita ShvedSchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Mikhail GarbuzSchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Grigorii MalykinSchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Valeriia GulaiaSchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Alexander KaganskySchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Vadim KumeikoSchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Far Eastern Federal University · RUA.V. Zhirmunsky National Scientific Center of Marine Biology Far Eastern Branch of the Russian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During cancer genesis, the extracellular matrix (ECM) in the human brain undergoes important transformations, starting to resemble embryonic brain cell milieu with a much denser structure. However, the stiffness of the tumor ECM does not preclude cancer cells from migration. The importance of the ECM role in normal brain tissue as well as in tumor homeostasis has engaged much effort in trials to implement ECM as a target and an instrument in the treatment of brain cancers. This review provides a detailed analysis of both experimental and applied approaches in combined therapy for gliomas in adults. In general, matrix materials for glioma treatment should have properties facilitating the simplest delivery into the body. Hence, to deliver an artificial implant directly into the operation cavity it should be packed into a gel form, while for bloodstream injections matrix needs to be in the form of polymer micelles, nanoparticles, etc. Furthermore, the delivered material should mimic biomechanical properties of the native tissue, support vital functions, and slow down or stop the proliferation of surrounding cells for a prolonged period. The authors propose a two-step approach aimed, on the one hand, at elimination of remaining cancer cells and on the other hand, at restoring normal brain tissue. Thereby, the first bioartificial matrix to be applied should have relatively low elastic modulus should be loaded with anticancer drugs, while the second material with a higher elastic modulus for neurite outgrowth support should contain specific factors stimulating neuroregeneration.

Indexed as

biocompatible materialcancer treatmentCNS reconstructiondrug deliveryextracellular matrixglioblastomaneuroregeneration

Identifiers

PMID31803736
PMCPMC6877546
OpenAlexW2991046110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.